Shots:

• The P-I CHRYSALIS study evaluates the safety- PK- and preliminary efficacy of Rybrevant (1050/1400 mg) as a monothx. and in combinations with lazertinib in 19 patients with NSCLC with METex14 mutations
• The initial data showed anti-tumor activity and a consistent safety profile with reported experience at the approved P-II dose. Disease response was evaluated using ORR- 64% showed partial response while the median time to 1st response was 4.1mos.
• In May’21- the therapy received FDA’s approval for LA or metastatic NSCLC EGFR exon 20 insertion mutations- based on data which showed ORR (40%) and m-DoR of 11.1mos.

  Ref: PR Newswire | Image: Janssen